Missed Regeneron Pharmaceuticals' Rally? Here Is What Holders Saw

Simply Wall St.11-13 17:20

Radiopharmaceuticals do not usually move a biotech’s share chart on their own, yet Regeneron Pharmaceuticals’ $4.3b collaboration with Telix on solid tumor therapies gave investors a fresh, concrete ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2683604576?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118","is_english":true,"pubTime":"2026-11-13 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2683604576","market":"us","top_or_hot":-1,"title":"Missed Regeneron Pharmaceuticals' Rally? Here Is What Holders Saw","media":"Simply Wall St.","content":"<div>\n<p>Radiopharmaceuticals do not usually move a biotech’s share chart on their own, yet Regeneron Pharmaceuticals’ $4.3b collaboration with Telix on solid tumor therapies gave investors a fresh, concrete ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/missed-regeneron-pharmaceuticals-rally-here-is-what-holders\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Regeneron Pharmaceuticals' Rally? Here Is What Holders Saw</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Regeneron Pharmaceuticals' Rally? Here Is What Holders Saw\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-13 17:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/missed-regeneron-pharmaceuticals-rally-here-is-what-holders><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Radiopharmaceuticals do not usually move a biotech’s share chart on their own, yet Regeneron Pharmaceuticals’ $4.3b collaboration with Telix on solid tumor therapies gave investors a fresh, concrete ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/missed-regeneron-pharmaceuticals-rally-here-is-what-holders\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/missed-regeneron-pharmaceuticals-rally-here-is-what-holders","article_id":"2683604576","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/33715-card/1789122008118"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/missed-regeneron-pharmaceuticals-rally-here-is-what-holders","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2683604576","pubTimestamp":1794561602,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 13, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","REGN":"再生元制药公司","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BBH":"VanEck Biotech ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK4585":"ETF&股票定投概念","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4139":"生物科技"},"translate_title":"错过了再生元制药的集会？以下是持有者所看到的","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TBXU":0.6,"REGN":1.5,"BBH":0.6,"IBB":0.6,"IBBQ":0.6},"content_text":"Radiopharmaceuticals do not usually move a biotech’s share chart on their own, yet Regeneron Pharmaceuticals’ $4.3b collaboration with Telix on solid tumor therapies gave investors a fresh, concrete bet to consider this year. Investors who held Regeneron Pharmaceuticals over the past year are up 37.6%, including dividends. If you were deciding back on 2025-11-12, what did you need to believe about these kinds of deals and the broader pipeline to feel that this outcome was plausible? The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with. The move put Regeneron Pharmaceuticals in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it. AdvertisementThe Two Stories Regeneron Investors Had To Weigh The shares cost US$682 at the start of the period, so anyone looking at Regeneron Pharmaceuticals had to decide which story seemed more reasonable. The bullish narrative pointed to a fair value of US$722, based on assumptions like 5.4% annual revenue growth and a future P/E of 16.1x, plus confidence that Dupixent and a broad pipeline would support earnings. The bearish view put fair value at US$540 and focused on pressures. That script leaned on slow 1.4% revenue growth assumptions and the risk that healthcare reforms and biosimilars would erode margins to 22.5%. NasdaqGS:REGN 1-Year Stock Price Chart What The Evidence Did To The Regeneron Pharmaceuticals Argument Regeneron Pharmaceuticals’ Telix radiopharmaceutical alliance, along with new deals with Parabilis and CytomX and multiple positive trial and regulatory updates across cemdisiran, Lynozyfic, Otarmeni, Pasatru and CIDEB siRNA, leaned toward the bullish case that a broad pipeline could be important. The main caveat came from failed melanoma data and related securities lawsuits, which supported a cautious view on clinical and reputational risk. The period highlighted how much the original thesis depended on pipeline productivity rather than headlines about “innovation.” For a different stock, track whether promised late stage programs and partnerships are reflected in revenue, absolute profit and net margin within a few years of the decision date. What Regeneron’s One Year Run Already Prices In Regeneron Pharmaceuticals has climbed to US$951, after investors saw a 37.6% gain over the past year. The bearish analyst Narrative on Simply Wall St still places Fair Value below that share price, even while acknowledging strong execution across Dupixent, EYLEA HD and newer siRNA and antibody programs. The Narrative’s key concern is whether today’s valuation already assumes that pipeline assets mature smoothly into long lived profit streams. Anyone paying the current price needs to judge whether newer franchises can offset EYLEA competition, moderating Dupixent growth, higher research spend and legal risks over the next several years. \"As Regeneron Pharmaceuticals leans more heavily on its genetics, proteomics, siRNA and antibody engineering platforms to feed a roughly 50 program pipeline, there is a risk that higher ongoing research and development spending tied to these complex modalities outpaces incremental product contributions, which would weigh on operating margins and limit growth in net income even if headline revenue continues to rise.\" Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there Beyond Regeneron’s Radiopharmaceutical Story Regeneron offers one view of complex biologic pipelines and platform bets. It is not the only approach to chronic disease exposure. Another large drug maker is building a broad cardiometabolic and obesity franchise around incretin therapies and related combinations. It is also expanding in oncology, neuroscience, immunology and vaccines. The shared thread is long term demand for chronic treatments, not any direct connection between these medicines. Each business is working to convert wide pipelines into durable product lines. For your watchlist, that raises a practical question. How might a multi drug obesity and diabetes platform reshape what core pharmaceutical earnings look like? One Narrative has already put a figure on it. → Uncover the company trading 13% below one Narrative's Fair Value This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2683604576","isCrawlerRequest":true}